Is There a Role for Preoperative 5 Alpha Reductase Inhibitors in Reducing Prostate Vascularity and Blood Loss?
- 216 Downloads
Benign prostatic hyperplasia (BPH) and the related medical problems are a major burden as health care costs and as a cause of patient morbidity. The introduction of medical therapy largely offered an alternative to surgical therapy, and these medications have been linked with multiple positive BPH-related outcomes. With ubiquitous use, however, a variety of adverse side effects and unsupported claims to these medications have been reported both in scientific literature and popular press. The use of 5 alpha reductase inhibitors (5ARIs) to reduce recurrent bleeding due to BPH is a reasonable option for men with recurrent trips to the physician or hospital. After a largely anecdotal report of their use in the preoperative period to reduce bleeding during BPH surgery, there was interest in the use of 5ARIs for this indication considering the effusive bleeding that can occur during BPH-related surgery, a dreaded and not uncommon complication. While the pathophysiology for the use of 5ARI to reduce BPH-related bleeding is sound, the actual clinical outcomes still require scrutiny to determine if the efficacy is both scientifically valid and clinically significant. This report will review the current literature on this topic and make attempts to determine if the use of a 5ARI before BPH-related surgery should be encouraged.
Keywords5 Alpha reductase inhibitor Benign prostatic hyperplasia Prostate surgery Finasteride Dutasteride
Compliance with Ethical Standards
Conflict of Interest
Matthew Bruha declares no potential conflicts of interest.
Charles Welliver reports honorarium from the American Society of Andrology, a paid reviewer for BMJ and Oakstone Publishing, and a consultant for Coloplast.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 1.American Urological Association. Management of Benign Prostatic Hyperplasia (BPH). 2014. http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014). Accessed 5 May 2017.
- 2.Welliver C, McVary KT. Minimally invasive and endoscopic management of benign prostatic hyperplasia. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh urology. 11th ed. Philadelphia, PA: Elsevier; 2015.Google Scholar
- 5.Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999;53(3):473–80.CrossRefPubMedGoogle Scholar
- 6.Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004;171(3):1194–8. doi: 10.1097/01.ju.0000112918.74410.94.CrossRefPubMedGoogle Scholar
- 7.Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2014;191(6):1828–34. doi: 10.1016/j.juro.2013.12.014.CrossRefPubMedGoogle Scholar
- 11.Tanner MJ, Welliver RC Jr, Chen M, Shtutman M, Godoy A, Smith G, et al. Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One. 2011;6(1):e16027. doi: 10.1371/journal.pone.0016027.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Ku JH, Shin JK, Cho MC, Myung JK, Moon KC, Paick JS. Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue. Scand J Urol Nephrol. 2009;43(6):445–53. doi: 10.3109/00365590903337896.CrossRefPubMedGoogle Scholar
- 27.Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003;169(1):20–3. doi: 10.1097/01.ju.0000039923.75777.91.CrossRefPubMedGoogle Scholar
- 29.Jia G, Heverhagen JT, Polzer H, Jacko RV, Liang J, Zhang J, et al. Dynamic contrast enhanced magnetic resonance imaging as a biological marker to noninvasively assess the effect of finasteride on prostatic suburethral microcirculation. J Urol. 2006;176(5):2299–304. doi: 10.1016/j.juro.2006.07.056.CrossRefPubMedGoogle Scholar
- 32.Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol. 2002;168(5):2024–6. doi: 10.1097/01.ju.0000028607.29093.56.CrossRefPubMedGoogle Scholar
- 35.• Hahn RG, Fagerstrom T, Tammela TL, Van Vierssen TO, Beisland HO, Duggan A, et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int. 2007;99(3):587–94. doi: 10.1111/j.1464-410X.2006.06619. This study is the largest and most rigorous study examining the use of a 5ARI in men. Clinical outcomes were not convincingly improved through the use of Dutasteride CrossRefPubMedGoogle Scholar
- 36.Kaplan SA, Lee JY, Meehan AG, Kusek JW, Group MR. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011;185(4):1369–73. doi: 10.1016/j.juro.2010.11.060.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Busetto GM, Giovannone R, Antonini G, Rossi A, Del Giudice F, Tricarico S, et al. Short-term pretreatment with a dual 5alpha-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int. 2015;116(1):117–23. doi: 10.1111/bju.12917.CrossRefPubMedGoogle Scholar
- 38.• Zhu YP, Dai B, Zhang HL, Shi GH, Ye DW. Impact of preoperative 5alpha-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC Urol. 2015;15:47. doi: 10.1186/s12894-015-0043-4. This meta-analysis of controlled trials found fairly minor effects of 5ARI but included studies with heterogeneous study designs and varied outcomes CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Aminsharifi A, Salehi A, Noorafshan A, Aminsharifi A, Alnajar K. Effect of preoperative finasteride on the volume or length density of prostate vessels, intraoperative, postoperative blood loss during and after monopolar transurethral resection of prostate: a dose escalation randomized clinical trial using stereolog methods. Urol J. 2016;13(1):2562–8.PubMedGoogle Scholar